Metanomics Health Information

Biocrates and Metanomics Health have merged to create a new global leader in Metabolomics and early disease detection. As a total solution provider, Biocrates and Metanomics Health provide the broadest technology and product portfolio in the industry. In addition to our unique metabolomics services offer, our team is developing new clinical biomarker assays addressing unmet medical needs as well as quality control assays to improve clinical study outcomes. Our cutting-edge technology includes state-of-the-art statistics, proprietary bioinformatics tools and biomedical expert interpretation of high quality data sets. We provide unique information about mechanisms of action, new drug targets and predictive drug safety. These decision-enabling biomedical data can accelerate drug development by reducing risk, increasing efficacy, and helping to identify therapy responders. Our Biomarker Program is focused on new diagnostic metabolic biomarkers, e.g. for congestive heart failure (CHF), early diagnosis of pancreatic cancer (PDAC), patient stratification for lung cancer treatment (LCA), non-alcoholic steatohepatitis (NASH), breast cancer (BCA), and ovarian cancer (OVCA). We are looking for collaboration partners from the pharma, nutrition, and biotech industry, as well as from universities and academic centers to further develop and market our biomarker projects. Interested in metabolomics by Metanomics Health GmbH/Biocrates Life Sciences AG? Visit www.metanomics-health.com or www.biocrates.com for more information.